SEC Comment Letter 0000000000-24-011156 to BIOMARIN PHARMACEUTICAL INC (BMRN)

BIOMARIN PHARMACEUTICAL INC
Date: Oct. 3, 2024 · CIK: 0001048477 · Accession: 0000000000-24-011156

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-26727

Date

October 3, 2024

Author

Brian Mueller

Form

UPLOAD

Company

BIOMARIN PHARMACEUTICAL INC

Letter

October 3, 2024 Brian Mueller Chief Financial Officer BioMarin Pharmaceutical Inc. 770 Lindaro Street San Rafael, California 94901 Re:BioMarin Pharmaceutical Inc. Form 10-K for the fiscal year ended December 31, 2023 Filed February 26, 2024 Form 10-Q for the quarterly period ended June 30, 2024 Filed August 5, 2024 File No. 000-26727 Dear Brian Mueller: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Eric Davis

Show Raw Text

October 3, 2024
Brian Mueller
Chief Financial Officer
BioMarin Pharmaceutical Inc.
770 Lindaro Street
San Rafael, California 94901
Re:BioMarin Pharmaceutical Inc.
Form 10-K for the fiscal year ended December 31, 2023
Filed February 26, 2024
Form 10-Q for the quarterly period ended June 30, 2024
Filed August 5, 2024
File No. 000-26727
Dear Brian Mueller:
            We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Eric Davis

SecProbe.io